These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 19907719)

  • 1. Cevipabulin (TTI-237): preclinical and clinical results for a novel antimicrotubule agent.
    Ayral-Kaloustian S; Zhang N; Beyer C
    Methods Find Exp Clin Pharmacol; 2009 Sep; 31(7):443-7. PubMed ID: 19907719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The microtubule-active antitumor compound TTI-237 has both paclitaxel-like and vincristine-like properties.
    Beyer CF; Zhang N; Hernandez R; Vitale D; Nguyen T; Ayral-Kaloustian S; Gibbons JJ
    Cancer Chemother Pharmacol; 2009 Sep; 64(4):681-9. PubMed ID: 19132373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TTI-237: a novel microtubule-active compound with in vivo antitumor activity.
    Beyer CF; Zhang N; Hernandez R; Vitale D; Lucas J; Nguyen T; Discafani C; Ayral-Kaloustian S; Gibbons JJ
    Cancer Res; 2008 Apr; 68(7):2292-300. PubMed ID: 18381436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microtubule active agents: beyond the taxane frontier.
    Morris PG; Fornier MN
    Clin Cancer Res; 2008 Nov; 14(22):7167-72. PubMed ID: 19010832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stabilization of microtubules by cevipabulin.
    Nasrin SR; Rashedul Kabir AM; Konagaya A; Ishihara T; Sada K; Kakugo A
    Biochem Biophys Res Commun; 2019 Aug; 516(3):760-764. PubMed ID: 31253401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models.
    Peterson JK; Tucker C; Favours E; Cheshire PJ; Creech J; Billups CA; Smykla R; Lee FY; Houghton PJ
    Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6950-8. PubMed ID: 16203787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HTI-286, a synthetic analogue of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo.
    Loganzo F; Discafani CM; Annable T; Beyer C; Musto S; Hari M; Tan X; Hardy C; Hernandez R; Baxter M; Singanallore T; Khafizova G; Poruchynsky MS; Fojo T; Nieman JA; Ayral-Kaloustian S; Zask A; Andersen RJ; Greenberger LM
    Cancer Res; 2003 Apr; 63(8):1838-45. PubMed ID: 12702571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microtubule alterations and resistance to tubulin-binding agents (review).
    Drukman S; Kavallaris M
    Int J Oncol; 2002 Sep; 21(3):621-8. PubMed ID: 12168109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticancer therapy with novel tubulin-interacting drugs.
    Kavallaris M; Verrills NM; Hill BT
    Drug Resist Updat; 2001 Dec; 4(6):392-401. PubMed ID: 12030786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical discovery of ixabepilone, a highly active antineoplastic agent.
    Lee FY; Borzilleri R; Fairchild CR; Kamath A; Smykla R; Kramer R; Vite G
    Cancer Chemother Pharmacol; 2008 Dec; 63(1):157-66. PubMed ID: 18347795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microtubule-damaging agents enhance RASSF1A-induced cell death in lung cancer cell lines.
    Whang YM; Park KH; Jung HY; Jo UH; Kim YH
    Cancer; 2009 Mar; 115(6):1253-66. PubMed ID: 19156899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemosensitization and radiosensitization of human lung and colon cancers by antimitotic agent, ABT-751, in athymic murine xenograft models of subcutaneous tumor growth.
    Jorgensen TJ; Tian H; Joseph IB; Menon K; Frost D
    Cancer Chemother Pharmacol; 2007 May; 59(6):725-32. PubMed ID: 16967299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microtubules: a dynamic target in cancer therapy.
    Pasquier E; Kavallaris M
    IUBMB Life; 2008 Mar; 60(3):165-70. PubMed ID: 18380008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor cells resistant to a microtubule-depolymerizing hemiasterlin analogue, HTI-286, have mutations in alpha- or beta-tubulin and increased microtubule stability.
    Poruchynsky MS; Kim JH; Nogales E; Annable T; Loganzo F; Greenberger LM; Sackett DL; Fojo T
    Biochemistry; 2004 Nov; 43(44):13944-54. PubMed ID: 15518543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anticancer Drug Development: The Way Forward.
    Connors T
    Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 7-Diethylamino-3(2'-benzoxazolyl)-coumarin is a novel microtubule inhibitor with antimitotic activity in multidrug resistant cancer cells.
    Kim SN; Kim NH; Park YS; Kim H; Lee S; Wang Q; Kim YK
    Biochem Pharmacol; 2009 Jun; 77(12):1773-9. PubMed ID: 19428332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo.
    Kuo CC; Hsieh HP; Pan WY; Chen CP; Liou JP; Lee SJ; Chang YL; Chen LT; Chen CT; Chang JY
    Cancer Res; 2004 Jul; 64(13):4621-8. PubMed ID: 15231674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epothilones: mechanism of action and biologic activity.
    Goodin S; Kane MP; Rubin EH
    J Clin Oncol; 2004 May; 22(10):2015-25. PubMed ID: 15143095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploring the mechanisms of action of the novel microtubule inhibitor vinflunine.
    Jordan MA; Horwitz SB; Lobert S; Correia JJ
    Semin Oncol; 2008 Jun; 35(3 Suppl 3):S6-S12. PubMed ID: 18538179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A-204197, a new tubulin-binding agent with antimitotic activity in tumor cell lines resistant to known microtubule inhibitors.
    Tahir SK; Han EK; Credo B; Jae HS; Pietenpol JA; Scatena CD; Wu-Wong JR; Frost D; Sham H; Rosenberg SH; Ng SC
    Cancer Res; 2001 Jul; 61(14):5480-5. PubMed ID: 11454695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.